ABCL:NASDAQAbCellera Biologics Inc. analysis
Data as of Aug 18, 2026 - not real-time
- Latest price
- $11.20
- Risk: high
- 9/10High risk
Summary
At $11.20, AbCellera Biologics Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. It has gained 42.3% over the past 30 days. RSI sits at 81.4, which reads as overbought, and MACD momentum is bullish. Price has been bracketed by support at $4.98 and resistance at $11.65.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 52.9% above the current quote. Revenue is contracting at 76.3% on a -248.8% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 117.7%, a beta of 2.62 and a maximum drawdown of 54.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 52.9% above the current quote. Revenue is contracting at 76.3% on a -248.8% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 117.7%, a beta of 2.62 and a maximum drawdown of 54.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
Top market events
- Vancouver biotech’s stock hit the highest level since early 2023 this week and is up 185% this year
- AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
- VANCOUVER, British Columbia, July 07, 2026--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- RSI at 81.4 signals overbought conditions
- Trading above the 200-day average of 4.64
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- RSI at 81.4 signals overbought conditions
- Trading above the 200-day average of 4.64
Long term
> 3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Negative profit margin of -248.8%
- Analyst targets imply +52.9% versus the current price
- Negative return on equity of -17.3%
Key metrics
Financial health
Revenue Growth-76.30%
Profit Margin-248.84%
P/E Ratio-15.7
ROE-17.30%
ROA-10.39%
Debt/Equity15.13
P/B Ratio3.8
Op. Cash Flow$-94937000
Free Cash Flow$-46431124
Industry P/E29.8
Technical analysis
TrendBullish
RSI81.4
Support$4.98
Resistance$11.65
MA 20$7.22
MA 50$6.72
MA 200$4.64
MACDBullish
VolumeIncreasing
Fear & Greed Index94.3
Valuation
Target Price$17.13
Upside/Downside52.90%
GradeFair
TypeBlend
Risk assessment
Beta2.62
Volatility117.74%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.